NASDAQ:RCKT Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis $2.18 -0.18 (-7.63%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$2.24 +0.05 (+2.52%) As of 10/16/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Rocket Pharmaceuticals Stock (NASDAQ:RCKT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rocket Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.17▼$2.3650-Day Range$2.18▼$3.8652-Week Range$2.17▼$5.45Volume1.97 million shsAverage Volume2.33 million shsMarket Capitalization$239.32 millionP/E RatioN/ADividend YieldN/APrice Target$7.77Consensus RatingHold Company Overview Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is a biotechnology company focused on developing gene therapies for rare and devastating diseases. The company uses both ex vivo hematopoietic stem cell gene therapy and in vivo adeno-associated virus (AAV) gene therapy approaches to address conditions with limited or no effective treatment options. Rocket’s development programs have included marnetegragene autotemcel (RP-L102) for leukocyte adhesion deficiency-I, a rare inherited immune disorder; RP-A501 for Danon disease, a genetic heart condition; RP-A601 for arrhythmogenic right ventricular cardiomyopathy associated with PKP2 mutations; and RP-L301 for pyruvate kinase deficiency, an inherited blood disorder. The company’s pipeline has also included additional programs targeting rare cardiovascular, hematologic and metabolic diseases. Founded in 2015 and headquartered in Cranbury, New Jersey, Rocket conducts research and clinical development through global programs and collaborations. The company is led by Chief Executive Officer Gaurav Shah, M.D., who has overseen its expansion as a developer of genetic medicines for patients with serious rare diseases.AI Generated. May Contain Errors. Read More Rocket Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreRCKT MarketRank™: 2.797116508635 of 5 starsRocket Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat, and ranked 317th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingRocket Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.42, and is based on 1 strong buy rating, 5 buy ratings, 4 hold ratings, and 2 sell ratings.Upside PotentialRocket Pharmaceuticals has a consensus price target of $7.77, representing about 256.5% upside from its current price of $2.18.Amount of Analyst CoverageRocket Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rocket Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Rocket Pharmaceuticals are expected to decrease in the coming year, from ($1.36) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rocket Pharmaceuticals is -12.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rocket Pharmaceuticals is -12.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRocket Pharmaceuticals has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Rocket Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.42% of the float of Rocket Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRocket Pharmaceuticals has a short interest ratio ("days to cover") of 6.94.Change versus previous monthShort interest in Rocket Pharmaceuticals has recently increased by 1.36%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRocket Pharmaceuticals does not currently pay a dividend.Dividend GrowthRocket Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.1 / 5News SentimentN/A News SentimentRocket Pharmaceuticals has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.Search InterestOnly 6 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat Follows5 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $432,273.00 in company stock.Percentage Held by Insiders21.30% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.39% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rocket Pharmaceuticals' insider trading history. Receive RCKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RCKT Stock News HeadlinesRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock Has Average Price Target of $7.77 According to BrokeragesOctober 10, 2026 | americanbankingnews.comRocket Pharmaceuticals Inc (RCKT)October 9, 2026 | za.investing.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 17 at 1:00 AM | Porter & Company (Ad)Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Rocket Pharmaceuticals (RCKT)October 9, 2026 | theglobeandmail.comWedbush Reaffirms "Outperform" Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)October 9, 2026 | americanbankingnews.comRocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Target Cut by Leerink PartnersOctober 9, 2026 | americanbankingnews.comRocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facilityOctober 7, 2026 | proactiveinvestors.comRocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor WebinarOctober 7, 2026 | businesswire.comSee More Headlines RCKT Stock Analysis - Frequently Asked Questions How have RCKT shares performed this year? Rocket Pharmaceuticals' stock was trading at $3.51 at the start of the year. Since then, RCKT stock has decreased by 37.9% and is now trading at $2.18. How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced its quarterly earnings results on Monday, August, 10th. The biotechnology company reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $0.86 by $0.22. When did Rocket Pharmaceuticals IPO? Rocket Pharmaceuticals (RCKT) raised $94 million in an initial public offering on Friday, February 6th 2015. The company issued 6,700,000 shares at $13.00-$15.00 per share. Who are Rocket Pharmaceuticals' major shareholders? Top institutional investors of Rocket Pharmaceuticals include Sanders Morris Harris LLC (0.03%). Insiders that own company stock include Gaurav Shah, Martin Wilson, Christopher James Stevens, Gotham Makker, Sarbani Chaudhuri, Jonathan David Schwartz, Aaron Ondrey, David P Southwell, David P Southwell, John Militello, Mark Andrew White, Elisabeth Bjork and Kinnari Patel. View institutional ownership trends. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rocket Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rocket Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Pfizer (PFE), Micron Technology (MU), Alibaba Group (BABA), Tesla (TSLA) and Intel (INTC). Company Calendar Last Earnings8/10/2026Today10/17/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, RCKT's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RCKT CIK1281895 Webwww.rocketpharma.com Phone(609) 659-8001Fax646-224-9585Employees202Year Founded2018Price Target and Rating Average Price Target for Rocket Pharmaceuticals$7.77 High Price Target$15.00 Low Price Target$2.95 Potential Upside/Downside+256.5%Consensus RatingHold Rating Score (0-4)2.42 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$223.12 million Net MarginsN/A Pretax MarginN/A Return on Equity-52.77% Return on Assets-44.92% Debt Debt-to-Equity Ratio0.05 Current Ratio9.24 Quick Ratio9.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.56 per share Price / Book0.85Miscellaneous Outstanding Shares109,780,000Free Float86,393,000Market Cap$239.32 million OptionableOptionable Beta0.50 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:RCKT) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RCKT Stock Alerts